Access to medicinal cannabis isn’t just an issue for patients in the US. For our neighbors across the pond in the UK, patients face an uphill battle to access cannabis-based medicine.
In a much-anticipated move, the UK’s National Health Service (NHS) announced this week that it will allow the administration of certain cannabis-derived drugs for serious medical conditions.
Patients with severe epilepsy and multiple sclerosis can access cannabis-derived medication, although medical cannabis itself as we know it in the US isn’t available in the UK.
The UK has taken a very conservative stance against medical cannabis. This has led to 1.4 million patients buying cannabis on the black market to manage their pain or medical issues. While the UK has a long way to go for embracing medical cannabis, patients can see hope on the horizon.
The National Institute for Health and Care Excellence (NICE) is a drug advisory board for the UK; it determines which drugs can be used to treat which conditions. The institute finally gave the green light for treating childhood epilepsy and multiple sclerosis with approved cannabis-derived medicines.
NICE approved two drugs: Epidyolex and Sativex. Epidyolex uses cannabidiol, or CBD, to reduce seizures and it’s now approved for children. Some studies say it can reduce seizures by as much as 40%. Sativex is a spray medication that helps people with multiple sclerosis treat muscle stiffness.
While patient advocates in the UK celebrated the change, many say this doesn’t go far enough. THC still isn’t allowed to be present whatsoever in children’s medication, and THC also isn’t allowed to be used as a painkiller in lieu of problematic opioids.
These two drugs will be available to patients starting in January 2020. The cannabis industry will be waiting with bated breath to see when the UK finally embraces cannabis.
Although Florida lifted its ban on smokable medical cannabis in March 2019, we’re just now seeing the downstream effects of that decision. Now that medical
In an article published by The Philadelphia Inquirer, author Sam Wood, highlights the accomplishment of a congressional committee voting to end federal
The fall semester of the 2019 - 2020 school year has been one for the record books for universities across the US. As the end of the first semester approaches
In an article published by The Philadelphia Inquirer, author Sam Wood, explores the purchase of a South Jersey medical marijuana cultivator and retailer
An article published by Leafreport earlier this week discusses celebrities such as Kourtney Kardashian, Mike Tyson, and John Legend, all having the same
In November 2018, Massachusetts went legal for adult use. At the time, there were two dispensaries, and the people of Massachusetts spent $440,000 on weed.